What should you know about approved antibody drug conjugates?

An antibody-drug conjugate has an antibody that recognises a selected target, a chemical linker, and an attached payload. After the antibody binds to its target on a cancer cell, the conjugate may enter the cell and release the payload. This design concentrates drug delivery around cells carrying the target, although healthy tissues can still be affected.

Approval applies to a particular medicine in defined clinical circumstances; it does not make every conjugate suitable for every cancer. The tumour type, biomarker result, previous treatment, organ function, current medicines, and local indication all inform the choice. Two medicines in this class can have different targets, payloads, schedules, and safety concerns.

Ask which biomarker makes the treatment relevant and how your sample was tested. Give the oncology team an up-to-date list of medicines and supplements, and describe previous reactions to cancer therapy. Depending on the chosen drug, the team may check blood counts, liver function, heart function, breathing symptoms, vision, or other baseline measures.

Before each dose, report changes rather than waiting for them to become severe. Follow the drug-specific instructions for managing nausea, mouth soreness, bowel changes, fatigue, skin problems, or eye irritation. Do not start non-prescription remedies or alter a dose without checking for interactions and confirming the plan with the treating team.

Call the oncology team urgently for fever, shaking chills, unusual bleeding or bruising, yellowing of the skin or eyes, repeated vomiting, severe diarrhoea, a painful spreading rash, or eye pain and new vision changes. New cough, breathlessness, or chest discomfort requires prompt assessment because some conjugates can inflame or damage lung tissue. Seek emergency help for severe difficulty breathing, fainting, facial or throat swelling, or a rapidly worsening reaction during or after an infusion.

What target does this conjugate recognise, and did my tumour test positive for it? What is the goal of treatment? Which side effects are especially associated with this medicine? What monitoring will I need before and between doses? Who should I contact after hours if breathing, fever, bleeding, eye, or infusion symptoms occur?